Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06839833 · ClinicalTrials.gov registry record · NA
APOL1 Genotyping CTA Clinical Performance Study
A NA study of APOL1-mediated Kidney Disease, sponsored by Almac Diagnostic Services.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT06839833: Recruiting NA study of APOL1-mediated Kidney Disease, sponsored by Almac Diagnostic Services.
NCT06839833 is a NA study of APOL1-mediated Kidney Disease that is actively recruiting participants, run by Almac Diagnostic Services. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06839833, a NA study of APOL1-mediated Kidney Disease, is actively recruiting participants, sponsored by Almac Diagnostic Services.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Clinical Performance Study SP2024001, is a prospective, interventional study to assess the clinical performance of the APOL1 Genotyping Clinical Trial Assay (CTA) in the intended use population and environment. The study will use the APOL1 Genotyping CTA to test deoxyribonucleic acid (DNA) extracted from blood specimens to identify individuals who are homozygous or compound heterozygous for apolipoprotein L1 (APOL1) high-risk genotypes (G1 and G2).The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).
Primary Outcome
To utilize the APOL1 Genotyping CTA as a screening test to identify participants homozygous or compound heterozygous for high risk APOL1 genotypes (G1/G2) for inclusion in a Ph 2b trial
Conditions Studied
Interventions
- DIAGNOSTIC_TEST APOL1 Genotyping
Study Locations (1)
North Carolina
- Almac Diagnostic Services LLC - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2026-03 |
| Phase | NA |
What NCT06839833 shows while recruiting
NCT06839833 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 1 condition, with APOL1-mediated Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which APOL1 Genotyping is the first listed.
NCT06839833 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06839833 about?
NCT06839833 is a clinical study titled "APOL1 Genotyping CTA Clinical Performance Study". Clinical Performance Study SP2024001, is a prospective, interventional study to assess the clinical performance of the APOL1 Genotyping Clinical Trial Assay (CTA) in the intended use population and environment. The study will use the APOL1 Genotyping CTA to test deoxyribonucleic acid (DNA) extracted...
What is the current status of trial NCT06839833?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-03-06. Estimated completion is 2026-03.
What conditions does trial NCT06839833 study?
This clinical trial studies the following conditions: APOL1-mediated Kidney Disease.
What interventions are being tested in trial NCT06839833?
The interventions under investigation include: APOL1 Genotyping (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06839833?
This trial is sponsored by Almac Diagnostic Services, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06839833 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for APOL1-mediated Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06839833's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,881 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI